Showing 1821-1830 of 9336 results for "".
- Lubriderm Launches Skin Scholarship with the National Hispanic Health Foundationhttps://practicaldermatology.com/news/lubriderm-launches-skin-scholarship-with-the-national-hispanic-health-foundation/2461030/Lubriderm is partnering with the National Hispanic Health Foundation (NHHF) to create the Skin Scholarship sponsored by Lubriderm. This dedicated scholarship program will award $150,000 to ten U.S. Hispanic (USH), in addition to non-USH, full-time medical students and residents focused on a career…
- Avita Medical's Spray-On Skin Cells Demonstrate Proof of Concept in Aging Skin and EBhttps://practicaldermatology.com/news/avita-medicals-spray-on-skin-cells-demonstrate-proof-of-concept-in-rejuvenation-and-eb/2461028/Preclinical data successfully established proof of concept for Avita Medical’s Spray-On Skin Cells in skin rejuvenation and epidermolysis bullosa (EB), the company reports. AVITA Medical’s first US product, the RECELL System, was approved by FDA in September 2018. The RECELL System is indicated fo…
- Drug Combination Boosts Progression-free Survival in Advanced Melanomahttps://practicaldermatology.com/news/drug-combination-boosts-progression-free-survival-in-advanced-melanoma/2461027/Combining relatlimab and nivolumab (Opdivo) may double progression-free survival in patients with advanced melanoma, according to a new study in the New England Journal of Medicine. Relatlimab, which blocks a protein called LAG-3, is not yet approved, but the U.S. Food and Drug Administration has …
- Survey: Consumers Interested in Medical Cannabis Products for Inflammatory Skin Disordershttps://practicaldermatology.com/news/survey-consumers-interested-in-medical-cannabis-products-for-inflammatory-skin-disorders/2461025/Patients with dermatologic conditions are open to trying medical cannabis products (MCPs) as potential treatments, according to a new study from George Washington University (GW) School of Medicine and Health Sciences (SMHS) and University of Maryland researchers. “MCPs, which are cannabis or cann…
- First Patient Enrolled in Phase 2b Study of Oral Orismilast in Psoriasishttps://practicaldermatology.com/news/first-patient-enrolled-in-phase-2b-study-of-oral-orismilast-in-psoriasis/2461024/The first patient has been enrolled in IASOS, a Phase 2b dose-ranging study evaluating the safety and efficacy of oral orismilast in patients with moderate to severe psoriasis, according to UNION therapeutics. Orismilast is a next generation PDE4 inhibitor with broad anti-inflammatory properties a…
- The American Skin Association Re-ups Support for the SPOTS Programhttps://practicaldermatology.com/news/the-american-skin-association-re-ups-support-for-the-spots-program/2461023/The American Skin Association (ASA) is renewing its support for the SPOTS (Sun Protection Outreach Teaching by Students) program. SPOTS is a public health outreach educational program aimed at both elementary school students and young teenagers. The comprehensive program, taught by medical schoo…
- Case Study Highlights Possible Role for Minimal Dose Radiotherapy in Severe Acne Keloidalis Nuchaehttps://practicaldermatology.com/news/case-study-highlights-possible-role-for-minimal-dose-radiotherapy-in-severe-acne-keloidalis-nuchae/2461021/Minimal dose radiotherapy may offer new hope for severe acne keloidalis nuchae (AKN), according to research in the Journal of the American Academy of Dermatology Case Reports. The study found that a minimal dose of radiation is required to treat AKN. The amount of radiation required to permanently…
- Tremfya Five-Year Data Show No New Safety Signalshttps://practicaldermatology.com/news/tremfya-five-year-data-show-no-new-safety-signs/2461016/New data published in the Journal of the American Academy of Dermatology show that Tremfya® (guselkumab) from Janssen demonstrates a favorable safety profile and is well tolerated in adult patients with moderate to severe psoriasis (PsO) for up to 5 years. This is the first report on immunogenicity…
- Otezla Becomes First Oral Psoriasis Treatment Approved Across All Disease Severitieshttps://practicaldermatology.com/news/otezla-becomes-first-oral-psoriasis-treatment-approved-across-all-disease-severities/2461014/Otezla® (apremilast) from Amgen is now approved for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy. This expanded indication makes Otezla the first and only oral treatment approved in adult patients with plaque psoriasis across all seve…
- Allergan Aesthetics Completes Acquisition of Solitonhttps://practicaldermatology.com/news/allergan-aesthetics-completes-acquisition-of-soliton/2461013/It’s official: Allergan Aesthetics, an AbbVie company, completed its acquisition of Soliton, Inc. The addition of Soliton and its technology complements Allergan Aesthetics' portfolio of non-invasive body contouring treatments to now include the RESONIC device. This device initially received U.S…